Tyra Biosciences, Inc. Common Stock TYRA
Analyst Ratings
- Consensus
- Buy — 11 Buy · 1 Hold · 0 Sell (12 analysts)
- Avg. Price Target
- $50.80 (+77.3% upside)
Key Stats
- Today's Range
- $24.51 – $29.56
- 50-Day Range
- $24.17 – $33.72
- 52-Week Range
- $9.96 – $40.65
- Volume
- 1.86 million shs
- Average Volume
- 604K shs
- Market Cap
- $1.71 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 4.83
- Price / Sales
- —
Short Interest
- Short Interest
- 1.24%
- Days to Cover
- 1.57
Financials (TTM)
- Revenue
- —
- Net Income
- $-148,565,000
- Net Margin
- —
- Return on Equity
- -42.01%
- Debt-to-Equity
- —
About Tyra Biosciences, Inc. Common Stock
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Related Stocks
Compare head-to-head: TYRA vs LLY·TYRA vs JNJ·TYRA vs ABBV·TYRA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.